SIC 2834 – Pharmaceutical Preparations
| Valuation | |
|---|---|
| Market Cap ($M) | 175.54 |
| Enterprise Value ($M) | 126.05 |
| Book Value ($M) | 293.11 |
| Book Value / Share | 2.67 |
| Price / Book | 0.60 |
| NCAV ($M) | 259.50 |
| NCAV / Share | 2.37 |
| Price / NCAV | 0.68 |
| Profitability (mra) | |
|---|---|
| Return on Invested Capital (ROIC) | -0.43 |
| Return on Assets (ROA) | -0.45 |
| Return on Equity (ROE) | -0.53 |
| Liquidity (mrq) | |
|---|---|
| Quick Ratio | 10.37 |
| Current Ratio | 10.37 |
| Balance Sheet (mrq) ($M) | |
|---|---|
| Current Assets | 316.46 |
| Assets | 350.07 |
| Liabilities | 56.97 |
| Debt | n/a |
| Equity | n/a |
| Income Statement (mra) ($M) | |
|---|---|
| Revenue | 0.00 |
| Operating Income | -154.07 |
| Net Income | -138.20 |
| Cash Flow Statement (mra) ($M) | |
|---|---|
| Cash From Operations | -118.01 |
| Cash from Investing | -218.80 |
| Cash from Financing | 161.21 |
(click for more detail) |
|
| File Date | Form | Activist 13D/G Investors | Ownership (%) |
Change (%) |
|---|---|---|---|---|
| 13G/A | Vanguard Group Inc | 4.90 | -3.02 | |
| 13G | Logos Global Management LP | 6.00 | 127.59 | |
| 13G/A | Bain Capital Life Sciences Fund, L.P. | 4.90 | -12.15 | |
| 13G/A | Fmr Llc | 13.10 | 62.71 | |
| 13G/A | Bb Biotech Ag | 4.90 | 10.14 | |
| 13G/A | Biotechnology Value Fund L P | 8.40 | 28.97 | |
| 13G/A | Price T Rowe Associates Inc /md/ | 1.00 | -64.03 | |
| 13G/A | Adage Capital Management, L.P. | 3.28 | ||
| 13G | BlackRock, Inc. | 7.20 | 0.00 |
| Top 13F Investors | Shares (1000) |
Change (%) |
Value ($1000) |
Change (%) |
|---|---|---|---|---|
(click for more detail) |
||||
| Date | Insider Trades | Code | Shares | Value |
|---|---|---|---|---|
(click for more detail) |
||||
| File Date | Form | SEC Filings |
|---|---|---|
| UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K | ||
| UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q | ||
| UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q | ||
| UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q | ||
(click for more detail) |
||
| Short Volume | |||
|---|---|---|---|
| Market Date | Short Volume | Total Volume | Short Volume Ratio |
| 334,135 | 1,155,304 | 28.92 | |
| 248,949 | 914,473 | 27.22 | |
| 315,356 | 850,839 | 37.06 | |
| 294,861 | 1,145,473 | 25.74 | |
(click for more detail) |
|||
| Similar Companies | |
|---|---|
| AMPH – Amphastar Pharmaceuticals, Inc. | AMRX – Amneal Pharmaceuticals, Inc. |
| ANAB – AnaptysBio, Inc. | APLS – Apellis Pharmaceuticals, Inc. |
| ARQT – Arcutis Biotherapeutics, Inc. |
Financial data and stock pages provided by
Fintel.io